Genitourinary Cancer

The information below is intended for use by health care providers only. Please consult with your health care provider for more information about clinical trials.

EA8153 Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel:The CHAARTED2 Trial

Study Details

  • Study Site/Tumor Location: Prostate
  • Study Location: All Premier
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Male
  • Principal Investigator: Dr. Gross
  • Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz

Study Contact Information

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer (VISION)

The primary objective of this study is to compare overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-PSMA-617 in addition to best supportive/best standard of care versus patients treated with best supportive/best standard of care alone.

Study Details

  • Study Site/Tumor Location: Prostate
  • Study Location: All Premier
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Male
  • Principal Investigator: Dr. Bane
  • Other Physicians who can consent: Sheth, Yanes

Study Contact Information